UK markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
329.36+16.77 (+5.36%)
As of 3:40PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close312.59
Open315.01
Bid329.66 x 1200
Ask330.00 x 1100
Day's range308.24 - 331.00
52-week range54.10 - 331.00
Volume3,520,992
Avg. volume3,254,084
Market cap79.547B
Beta (5Y monthly)N/A
PE ratio (TTM)59.88
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent

    BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022BioNTech is evaluating sustainable mRNA vaccine production capacities in Africa; the Company’s efforts are supported by the joint convening powers of the World Health Organization (WHO) and the Africa Centers for Disease Control and Prevention (Africa CDC)BioNTech’s Malaria project is part of the ‘eradicateMalaria’ initiative, led by the kENUP Foundation, to accelera

  • Globe Newswire

    Fighting Infectious Diseases on the African Continent

    The African continent carries a disproportionately high share of the global infectious disease burden. The extraordinary scientific progress made during the COVID-19 pandemic gives hope in addressing a range of life-threatening infectious diseases. The kENUP Foundation has been working with the World Health Organization, the Africa CDC, the European Commission, the European Investment Bank, BioNTech, and the Bill & Melinda Gates Foundation on sustainable solutions to infectious disease challenge

  • Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
    Business Wire

    Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

    NEW YORK & MAINZ, Germany, July 23, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500 million. In a separate announcement on June 10, 2021, Pfizer